奥西替尼治疗EGFR T790M突变的老年晚期肺腺癌患者1例
| 作者: |
1马丽丽,
1柳江
1 新疆维吾尔自治区人民医院肿瘤科，乌鲁木齐 830000 |
| 通讯: |
柳江
Email: liujiang@csco.org.cn |
| DOI: | 10.3978/j.issn.2095-6959.020.01.042 |
| 基金: | 新疆维吾尔自治区自然科学基金(2019D01C100)。 |
摘要
1例表皮生长因子受体(epithelial growth factor receptor，EGFR)基因第19外显子突变阳性肺腺癌患者接受第一代EGFR抑制剂(tyrosine kinase inhibitors，TKIs)治疗后，无进展生存期(progression-free survival，PFS)达31个月，此后病情进展，患者肺内病灶增大，行血液标本基因检测，提示T790M突变，予以奥希替尼靶向治疗19个月，2019年9月患者仍未达到PFS。奥希替尼治疗T790M突变老年肺腺癌，疗效确切,安全性较好，该例患者主要不良反应为腹泻。
关键词：
非小细胞肺癌；EGFR-TKI；T790M；吉非替尼；奥西替尼
An elderly patient with advanced lung adenocarcinoma with EGFR T790M mutation treated with osimertinib
CorrespondingAuthor: LIU Jiang Email: liujiang@csco.org.cn
DOI: 10.3978/j.issn.2095-6959.020.01.042
Foundation: This work was supported by the Natural Science Foundation of Xinjiang Uygur Autonomous Region, China (2019D01C100).
Abstract
One case of lung adenocarcinoma with epithelial growth factor receptor (EGFR) gene exon 19 sensitive deletion mutant was treated with the first generation of EGFR-TKIs, its progression-free survival (PFS) reached 31months.after patient progressed and the lung lesion increased, the EGFR gene test of the blood, which suggested that the T790M mutation. the target treatment of osimertinib was obtained for 19 months, the PFS has not been reached up to the submission. Osimertinib in the treatment of lung adenocarcinoma with T790M mutant had good efficacy and safety, the main adverse reaction of this patient was diarrhoea.
Keywords：
non-small cell lung cancer; epidermal growth factor receptor-tyrosine kinase inhibitor; T790M; gefitinib; osimertinib